化學(xué)修飾的iGb3類似物優(yōu)勢誘導(dǎo)NK細胞分泌Th1類細胞因子的分子機制研究
[Abstract]:Objective Natural killer T cells (NKT) are a special type of T lymphocytes capable of recognizing glycolipid antigens presented by non-classical MHC class I molecule CD1d and expressing NK and T cell surface markers NK1.1 and TCR.NKT cells via endogenous ligand sheath glycolipid iGb3 (isoglobotrihexosylceramide) and exogenous glycolipid binding. Activated human alpha-galactose ceramide (alpha-GalCer) can secrete many cytokines, such as IFN-gamma, IL-4 and IL-13, which play an important role in anti-tumor, anti-virus infection, autoimmune tolerance and autoimmune diseases. However, NKT cells can secrete both Th1 and Th2 cytokines, affecting iGb3 or alpha-GalCer. Glucolipid molecules will play a more extensive role in clinical application if effective ways can be found to actively regulate the relative production of two types of cytokines.
It was found that OCH, an analogue obtained by truncating the saddle alcohol chain of alpha-GalCer, could achieve the predominant secretion of IL-4 by lowering the stability of glycolipid molecule-CD1d complex and enhancing the affinity of glycolipid molecule-TCR. The analogue alpha-C-GalCer can prolong the time of interaction with C D1d and NKT cells by enhancing the stability of the links between the various parts of glycolipid molecules to achieve the predominant secretion of IFN-gamma. It is suggested that targeted modification of glycolipids can induce the secretion of Th1/Th2 cytokines in NKT cells. The functional and structural differences of NKT cells activated by glycolipids and lipids after modification were analyzed. However, there is no study on the modification of endogenous ligand iGb3.
In view of this, we modified iGb3 and alpha-GalCe, and obtained a number of chemically modified iGb3 and alpha-GalCe analogues. In the previous work, we screened two analogues 4-HO-iGb3 and 4''-dh-iGb3, which had the predominant ability to induce the secretion of Th1 cytokines in mouse liver NKT cells. The predominant secretion of cytokines from chemically modified iGb3 analogues was selected and determined. On this basis, the interaction between glycolipids/APC/TCR and some important factors affecting the secretion of NKT cytokines, such as cell microenvironment, were discussed in depth, which provided a new strategy and basis for the design and clinical application of glycolipids.
Methods (1) The number of NKT cells and the expression of intracellular cytokines IFN-gamma and IL-4 in liver and spleen of mice were detected by flow cytometry. (2) Differentiation and maturation of mouse bone marrow-derived dendritic cells were induced in vitro. (3) ELISA assay. The secretion levels of cytokines IFN-gamma and IL-4 in serum and cell culture supernatant of mice treated with chemically modified iGb3 analogues were measured. (4) The gene expression of IFN-gamma, IL-4, GATA-3 and T-bet in splenic lymphocytes of mice was detected by real-time quantitative PCR. (5) QSAR software was used to analyze TCR receptors on glycolipids and NKT cells and CD1d on APC cells. (6) The expression of T-bet and GATA-3 in spleen lymphocytes of mice was detected by Western blot.
Result
First, the predominance of chemically modified iGb3 analogue 4'''-dh-iGb3 induces the secretion of IFN-gamma by mouse liver and spleen NKT cells
Intraperitoneal injection of iGb3 and its analogues into C57BL/6 mice showed that chemically modified iGb3 analogue 4'''-dh-iGb3 did not increase the proportion and number of NKT cells in the liver and spleen, but significantly increased the expression of IFN-gamma in the NKT cells of the liver and spleen, the secretion of IFN-gamma and the level of IFN-gamma in the serum, and the expression of Th2 cytokine IL-4. The expression of cytokines in NKT cells and the content of cytokines in supernatant were detected by stimulating NKT cell lines in vitro with bone marrow derived DC loaded with glucose and lipid.
Two, 4 '' -dh-iGb3 can enhance the binding strength and stability between glycolipid and CD1d, glycolipid and NKT cell TCR.
QSAR software was used to simulate the spatial structure of glycolipid, CD1d molecule of antigen-presenting cells and TCR molecule of NKT cells on a computer. It was found that introducing HO into the saddle alcohol chain of iGb3 could form a hydrophobic bond, which could directly penetrate into the hydrophobic formation of CD1d molecule along with the existing HO in the original acyl chain. The affinity between the glycolipid and the amino acid Asp80 (C) on the C D1d molecule was enhanced by binding the sex antigen in the pocket, and the space position of the glycolipid binding to the amino acid Lys167 on the TCR molecule was changed from the one side of the glycolipid to the other side of the glycolipid by deoxidizing the glycolipid, so that the binding fraction between the glycolipid and the TCR was increased from 3.3 to 4.9, and the binding fraction between the glycoli The binding ability of 4''''-dh-iGb3 to TCR of NKT cells is that the modified 4'''-dh-iGb3 has stronger affinity to CD1d molecule of antigen-presenting cells and stability to TCR of NKT cells than that of iGb3.
3,4'''-dh-iGb3 up-regulates the phosphorylation of Th1 cytokine-related transcription factor STAT1 and the expression of T-bet
After intraperitoneal injection of iGb3 and its analogues into C57BL/6 mice or stimulation of NKT cell lines in vitro, the expression of Th1/Th2 cytokine-related transcription factors regulated by NKT cells was observed. Compared with iGb3, 4'''-dh-iGb3 could up-regulate the phosphorylation of STAT1 and T-bet of Th1 cytokines produced by NKT cells. The phosphorylation of STAT6 and the expression of GATA-3, which regulate the production of Th2 cytokines, were not significantly different.
Conclusion (1) iGb3 analogue 4'''-dh-iGb3 can induce the predominant secretion of Th1 cytokines IFN-gamma. (2) 4''-dh-iGb3 can enhance the stability and affinity between glucose and lipid and TCR of NKT cells, thereby promoting the activation of NKT cells and the secretion of Th1 cytokines. The phosphorylation of STAT1 and the expression of T-bet, which control the differentiation of Th1/Th2, promote the expression and secretion of IFN-gamma in NKT cells. (4) 4'''-dh-iGb3 can be used as a new immunopotentiator in the treatment of tumor and infectious diseases.
【學(xué)位授予單位】:山東省醫(yī)學(xué)科學(xué)院
【學(xué)位級別】:碩士
【學(xué)位授予年份】:2009
【分類號】:R392
【相似文獻】
相關(guān)期刊論文 前10條
1 胡丙民;;核桃仁健腦益智[J];食品與健康;2002年11期
2 張犁;王旭;葉麗芳;徐彥;朱清毅;袁琳;蘇健;;中西醫(yī)結(jié)合治療2型糖尿病并發(fā)泌尿系統(tǒng)感染[J];江蘇醫(yī)藥;2011年11期
3 辛俊英;;不同體重多囊卵巢綜合征患者內(nèi)分泌和代謝相關(guān)指標(biāo)分析[J];海南醫(yī)學(xué)院學(xué)報;2011年10期
4 韓麗蓓;李小玲;劉金鳳;崔紅霞;王麗娟;;原發(fā)性血脂異常與2型糖尿病合并血脂異常中醫(yī)證素及血脂指標(biāo)對照研究[J];北京中醫(yī)藥大學(xué)學(xué)報(中醫(yī)臨床版);2011年04期
5 ;[J];;年期
6 ;[J];;年期
7 ;[J];;年期
8 ;[J];;年期
9 ;[J];;年期
10 ;[J];;年期
相關(guān)會議論文 前10條
1 劉青芝;郭學(xué)平;;槐糖脂的微生物合成及其應(yīng)用研究進展[A];2010年中國藥學(xué)大會暨第十屆中國藥師周論文集[C];2010年
2 宋丹丹;梁生康;王江濤;;假絲酵母菌產(chǎn)槐糖脂的發(fā)酵條件優(yōu)化和理化性質(zhì)研究[A];中國化學(xué)會第十三屆膠體與界面化學(xué)會議論文摘要集[C];2011年
3 張勇;王勝旺;王福慶;;URSA中NKT細胞功能失調(diào)的實驗研究[A];中國免疫學(xué)會第四屆學(xué)術(shù)大會會議議程及論文摘要集[C];2002年
4 易紹瓊;高杰英;彭虹;王嵐;王華;張辰;;輻射對小鼠不同組織NKT細胞的影響[A];中國免疫學(xué)會第四屆學(xué)術(shù)大會會議議程及論文摘要集[C];2002年
5 張德芹;李玉紅;王濤;安雅婷;劉虹;王茜;;糖脂清對實驗性高脂血癥大鼠糖脂代謝的影響[A];全國第3屆臨床中藥學(xué)學(xué)術(shù)研討會論文集[C];2010年
6 黃勇;姜爾烈;王荷花;周征;劉慶國;周世勇;王玫;韓明哲;;人Vα24NKT細胞的體外擴增及其生物學(xué)特性研究[A];中華醫(yī)學(xué)會第八次全國血液學(xué)學(xué)術(shù)會議論文匯編[C];2004年
7 戢璐;謝華;陳敏;陳艷秋;孫建琴;高臻輝;李茹;黃承鈺;;高尿酸并糖脂異常人群膳食與運動調(diào)查分析[A];生命發(fā)展機遇——窗口期營養(yǎng)——達能營養(yǎng)中心第十二屆學(xué)術(shù)年會會議論文集[C];2009年
8 王則能;許亦農(nóng);侯海彤;陽振樂;姜桂珍;匡廷云;;一種新糖脂:Synechocystis sp PCC 6803的異養(yǎng)生長[A];全國植物光合作用、光生物學(xué)及其相關(guān)的分子生物學(xué)學(xué)術(shù)研討會論文摘要匯編[C];2001年
9 郭彩欣;P.Boullanger;劉濤;江龍;;糖脂功能化的聚聯(lián)乙炔囊泡的尺寸對變色檢測能力的影響[A];中國化學(xué)會第二十五屆學(xué)術(shù)年會論文摘要集(下冊)[C];2006年
10 王澤軍;徐承富;徐磊;虞朝輝;厲有名;;外周血NKT細胞比例變化與非酒精性脂肪性肝病的關(guān)系[A];2006華東地區(qū)消化病學(xué)學(xué)術(shù)大會論文匯編(浙江省分冊)[C];2006年
相關(guān)重要報紙文章 前10條
1 本報記者 李寧艷 通訊員 王伯明;“加料糖脂寧”連害兩命[N];烏魯木齊晚報;2010年
2 本報記者 潘從武 通訊員 劉芳;假“糖脂寧”事件暴真相[N];法制日報;2009年
3 馬曉華;奪命假“糖脂寧膠囊”何以暢通無阻[N];第一財經(jīng)日報;2009年
4 記者 劉劍 通訊員 王鑫生;東營暫未發(fā)現(xiàn)奪命“糖脂寧膠囊”[N];東營日報;2009年
5 記者安淼;我市尚未發(fā)現(xiàn)假糖脂寧膠囊[N];秦皇島日報;2009年
6 記者 潘瑩;新疆:假“糖脂寧”源自遼寧,曾購者逾400[N];新華每日電訊;2009年
7 記者 冉亞雄;我省未發(fā)現(xiàn)假糖脂寧膠囊[N];河北日報;2009年
8 記者 張東風(fēng) 樊丹;衛(wèi)生部緊急叫!疤侵瑢幠z囊”[N];中國中醫(yī)藥報;2009年
9 記者 鄭惠華 通訊員 宋紅霞;糖脂寧膠囊未經(jīng)檢驗合格一律不得使用[N];河北經(jīng)濟日報;2009年
10 本報記者 劉盈蓉;我市暫未發(fā)現(xiàn)問題“糖脂寧膠囊”[N];湘潭日報;2009年
相關(guān)博士學(xué)位論文 前10條
1 張犁;糖脂清對2型糖尿病大鼠胰島β細胞功能的影響及機理研究[D];南京中醫(yī)藥大學(xué);2011年
2 姜擁軍;中國HIV/AIDS患者NK細胞及其相關(guān)表面標(biāo)志物研究[D];中國醫(yī)科大學(xué);2004年
3 張德芹;芪藍糖脂寧膠囊治療實驗性糖尿病合并高脂血癥的藥效學(xué)研究及機理探討[D];北京中醫(yī)藥大學(xué);2005年
4 胡紅梅;藥物和有氧運動防治糖尿病糖脂代謝紊亂機制的研究[D];華東師范大學(xué);2003年
5 黃勇;Vα24 NKT細胞的體外擴增和生物學(xué)功能研究[D];中國協(xié)和醫(yī)科大學(xué);2005年
6 王靜;小鼠肝臟免疫系統(tǒng)對自身免疫性肝損傷的調(diào)節(jié)機制[D];中國科學(xué)技術(shù)大學(xué);2006年
7 陳國江;抗CD3單克隆抗體治療Ⅰ型糖尿病及機制的研究[D];中國人民解放軍軍事醫(yī)學(xué)科學(xué)院;2007年
8 劉景華;同種異基因骨髓移植后α-GalCer的應(yīng)用加速免疫重建并未加重αGVHD[D];中國人民解放軍軍醫(yī)進修學(xué)院;2009年
9 李博峰;白細胞介素15負調(diào)節(jié)NKT細胞并抑制NKT細胞介導(dǎo)的肝炎[D];中國科學(xué)技術(shù)大學(xué);2006年
10 郭蓉姣;NKT細胞活化與C57BL/6J早孕小鼠流產(chǎn)機制的初步研究[D];暨南大學(xué);2008年
相關(guān)碩士學(xué)位論文 前10條
1 周志俠;化學(xué)修飾的iGb3類似物優(yōu)勢誘導(dǎo)NK細胞分泌Th1類細胞因子的分子機制研究[D];山東省醫(yī)學(xué)科學(xué)院;2009年
2 劉立真;IL-15、GM-CSF和腫瘤脂類粗提物對NKT細胞激活作用的實驗研究[D];中國人民解放軍軍醫(yī)進修學(xué)院;2002年
3 萬建R,
本文編號:2244316
本文鏈接:http://www.sikaile.net/yixuelunwen/shiyanyixue/2244316.html